Podcasts about UC

SUBSCRIBE to The One to Go Show presented by ImpactHealth SharingSoil & Ag Solutions- https://www.agconcepts.com/  320-219-3542Fast Lane Motorsports and powdercoating- http://www.fastlanemotorsports.orgEastCentral Sports- http://www.eastcentralsports.comFB- https://www.facebook.com/OnetoGoShowSpotify: https://open.spotify.com/episode/4fO19zPyhuwqb74Ut3jgho?si=clWSn-DVQkmp8W_f95p4IgTikTok- @theonetogoshowSnapchat-@theonetogoshowRumble:  https://rumble.com/v57phvx-71524-the-one-to-go-show-presented-by-impact-health-sharing.htmlYouTube: https://www.youtube.com/channel/UC_r_TSMx2XEfMfJ9Vc1ez0w?view_as=subscriberWe'd like to hear from you: theonetogoshow@gmail.comA productionof G.O.A.T. Sports Media LLC

Eric Lilly and Nick Niehaus team up for the midweek show, talking UC hoops and football. Find our shows on Chatterbox Sports YouTube Page.

More than 100,000 UC employees are suing President Trump, accusing him of trying to control what they say and teach. A stunning report on the LAPD exposes an oversized use of force against protesters. A man convicted in an 80s OC murder could soon be freed, because of a bad jail informant. Plus, more.Support The L.A. Report by donating at LAist.com/join and by visiting https://laist.comVisit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency! Support the show: https://laist.com

En el RatPack de Mesa Central, Iván Valenzuela y Angélica Bulnes conversaron con Pablo Ortúzar, antropólogo e investigador del IES y el Centro de Políticas Públicas UC sobre el ciclo político del país de cara a las elecciones y la relevancia del Frente Amplio una vez que termine la administración Boric.

Matt and Allie visit the Oxford PT Hamilton Center to talk to Lisa DeBord, PT MPT and her PT student Sela Maben. Sela shares her background, how she became interested in PT, and some fun stories about her past in Irish dancing! Sela shares her application process and why she ultimately chose UC. Sela is in her 12th week as a student PT intern with Oxford PT and has some great tips to share with other PT students and how school compares to real life/clinical experience. Lisa comments on how much she has seen Sela grow while working with her, and Sela also shares how Lisa as helped her build her confidence as well!Did you know that you don't need a doctor's prescription to receive physical therapy? The laws of Direct Access allow you to receive physical therapy without a referral and still use your insurance benefits! Learn more on how Direct Access can help YOU! Our website: https://www.oxfordphysicaltherapy.com/

Chad Brendel of Bearcat Journal joined us to talk about the UC football team and a new additon for Bearcat hoops, on ESPN1530.Podcasts of The Mo Egger Radio Show are a service of Longnecks Sports Grill.Listen to the show live weekday afternoons 3:00 - 6:00 on ESPN1530. Listen Live: ESPN1530.com/listenGet more: https://linktr.ee/MoEggerFollow on X: @MoEggerInstagram too: @MoEgger

Chad Brendel of Bearcat Journal joined us to talk about the UC football team and a new additon for Bearcat hoops, on ESPN1530.Podcasts of The Mo Egger Radio Show are a service of Longnecks Sports Grill.Listen to the show live weekday afternoons 3:00 - 6:00 on ESPN1530. Listen Live: ESPN1530.com/listenGet more: https://linktr.ee/MoEggerFollow on X: @MoEggerInstagram too: @MoEgger

Trace Talk มาอีกครั้ง กับรายการอัพเดตข่าวสารวงการเรื่องส่วนตัว และข่าวลี้ลับน่าสนใจจากทั่วโลก โดยยช ธัญ โจ้บองโก้ อีพีนี้พบกับ ความสามารถในการทายธงชาติของธัญและโจ้ / เปิดเพลย์ลิสต์เพลงร็อก Genie มิลเลเนียลสำหรับการวิ่งของธัญวัฒน์ / กิง ก่อง แก้ว 3 น้อนคาปิบาราใหม่แห่งสวนสัตว์เปิดเขาเขียว และวิธีการใช้งานชื่อน้อน / จู่ๆ ก็ถกกันเรื่อง Hive Mind, Collective Mind / แอนิเมชั่นใหม่ของ RiFF Studio คืน หลอก หลอน กับความสยองแบบแท็กซี่เจอผี / หมอผ่าตัดผู้สูญเสียขา กลายเป็นหนังคนละม้วน เมื่อถูกพบว่าทำไปเพื่อส่งเสริมความชอบรสนิยมส่วนตัว และฉ้อโกงเงินประกัน / ศาสดาลาพักร้อน เดอะมูฟวี่ โปรโมตไปก็เรียกทัวร์พุทโธเลี่ยนอีกแล้ว / วิชัยบุกห้องอัดช่วงท้าย เพราะอยากได้ห้องอัดมาทำงาน / และเรื่องอื่นๆ อีกมาก #SalmonLab #SalmonHouse #SalmonPodcast  #UntitledCase #UntitledCaseTraceTalk #ยชธัญ #UCTraceTalk #TraceTalk —--- ติดต่อโฆษณาได้ที่ podcast.salmon@gmail.com Follow Untitled Case on Instagram Salmon Podcast https://www.instagram.com/salmon_podcast/ ยช https://www.instagram.com/yodddddddd/ ธัญ https://www.instagram.com/thann401/ โจ้ https://www.instagram.com/jorborgor/ มาร่วมจอยคอมมูนิตี้ลึกลับของชาว UC ได้ที่กลุ่ม Untitled Club by Untitled Case https://www.facebook.com/groups/289112405610043 Learn more about your ad choices. Visit megaphone.fm/adchoices

A special episode this week, as the Megacanners are joined by journalist Wael Eskandar to talk about his journey from asking permission from the cops to buy an ice cream on Hermannplatz to watching them brutalize protesters with impunity on a weekly basis. Well done, Kai Wegner. — If only there was some kind of catastrophic lesson in German history to learn from to prevent this kind of thing. Prost! Megan's Megacan theme song by Eden Ottignon from ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Planet OTT⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Buy us a round, ask us a question! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/megansmegacan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Or follow us on whichever psychotic billionaire's data-fracking machine you prefer:⁠https://www.instagram.com/megansmegacan/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/megansmegacan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/MegansMegacan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UC-o_U5nqe4_-yKfOm1CXOPA⁠⁠⁠⁠

Mo is broadcasting live from the Kroger Queen City Championship with numerous guests talking Bengals/Jags, UC football, Reds and LPGA.

Mo is broadcasting live from the Kroger Queen City Championship with numerous guests talking Bengals/Jags, UC football, Reds and LPGA.

APAC stocks followed suit to the mixed performance stateside, where the S&P 500 and Nasdaq printed fresh record highs.US President Trump's administration appealed the court ruling blocking the removal of Fed Governor Cook.US Senate Republicans are aiming to confirm President Trump's temporary Federal Reserve pick Stephen Miran as soon as Monday, according to Politico, citing two sourcesEU is reportedly very unlikely to impose crippling tariffs on India or China, the main buyers of Russian oil, as US President Trump urged the bloc to do so, according to Reuters citing EU sources.European equity futures indicate a flat cash market open with Euro Stoxx 50 futures U/C after the cash market closed with losses of 0.1% on Wednesday.Looking ahead, highlights include US CPI (Aug) & Jobless Claims, ECB Policy Announcement & Press Conference, CBRT Announcement, IEA & OPEC Monthly Report, Supply from Italy and the US, and Earnings from Adobe.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

SUBSCRIBE to The One to Go Show presented by ImpactHealth SharingSoil & Ag Solutions- https://www.agconcepts.com/  320-219-3542Fast Lane Motorsports and powdercoating- http://www.fastlanemotorsports.orgEastCentral Sports- http://www.eastcentralsports.comFB- https://www.facebook.com/OnetoGoShowSpotify: https://open.spotify.com/episode/4fO19zPyhuwqb74Ut3jgho?si=clWSn-DVQkmp8W_f95p4IgTikTok- @theonetogoshowSnapchat-@theonetogoshowRumble:  https://rumble.com/v57phvx-71524-the-one-to-go-show-presented-by-impact-health-sharing.htmlYouTube: https://www.youtube.com/channel/UC_r_TSMx2XEfMfJ9Vc1ez0w?view_as=subscriberWe'd like to hear from you: theonetogoshow@gmail.comA productionof G.O.A.T. Sports Media LLC

Send us a textImagine visiting your gastroenterologist and feeling comfortable enough to discuss every aspect of how IBD affects your life—including your sexual health and practices. For many patients, particularly those in the LGBTQI+ community, this remains an elusive dream rather than reality.Dr. Victor Chedid, gastroenterologist and director of Mayo Clinic's Pride Clinic, joins Bowel Moments to tackle this crucial gap in IBD care. With disarming honesty and clinical expertise, he reveals why addressing sexuality isn't just about inclusivity—it's about providing complete medical care. When 95% of providers believe discussing sexual health is important but only 27% actually do it, patients suffer in silence with questions that directly impact their quality of life.The conversation dives deep into practical approaches for both patients and providers. Dr. Chedid shares his framework for discussing sexual practices with patients, from the straightforward question "What do you do for sex?" to navigating complex conversations around surgical interventions like J-pouch formation. For transgender patients, he unpacks recent research on gender-affirming hormones and IBD, emphasizing that life-saving gender-affirming care should never be withheld due to IBD concerns.Perhaps most compelling is Dr. Chedid's perspective on cultural humility and intersectionality. Each patient's experience is shaped by multiple overlapping identities—their sexuality, gender, race, nationality, and more. Rather than making assumptions, he advocates for providers to "leave their biases at the door" and approach each person's unique situation with curiosity and respect."People living with IBD are the experts of their own bodies," Dr. Chedid reminds us in his powerful closing thoughts. "When they say something feels off, it's not a guess—it's lived experience." This principle forms the foundation of truly inclusive care—care that sees patients as whole people deserving of dignity, understanding, and comprehensive treatment.Ready to advocate for more inclusive IBD care? Share this episode with your healthcare team and join the conversation about creating safe spaces for everyone in our community.Links: AGA's Pride Month Provider Spotlight on Dr. ChedidDr. Chedid talking about forming the IBD Pride Clinic"Your Top 6 Questions Answered by Dr. Victor Chedid" -A Program Dedicated to IBD Patients from the LGBTQIA+ Community- Crohn's & Colitis Foundation- USALet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Farmers could soon benefit from wheat engineered to stimulate the production of its own fertilizer, and the U.S. ag trade deficit hit a record high in the first half of this year.

Farmers could soon benefit from wheat engineered to stimulate the production of its own fertilizer, and the U.S. ag trade deficit hit a record high in the first half of this year.

In this episode, Tina is joined once again by integrative practitioner Curtis Gillespie Sayers to explore the role of peptides in managing ulcerative colitis (UC) and other autoimmune conditions. Curtis shares his expertise on how specific peptides can help reduce inflammation, support immune balance, and improve mitochondrial function. Together, they discuss why optimizing mitochondrial health is essential in UC management and outline practical considerations for incorporating peptides into a personalized healing plan. The conversation also covers potential side effects, the importance of individualized protocols, and why professional guidance is key for safe and effective use. Here's what you'll learn: - How peptides fit into the bigger picture of gut and immune system healing - The key immune-supportive peptides that can calm inflammation - Which peptides may help during a flare and how to use them safely - The best peptides for chronic, stubborn inflammation - The "Wolverine Stack"—what it is and why it's considered a powerful combo - BPC-157: injection vs capsule—what's the difference? - A suggested order for introducing peptides into a UC healing plan - How mitochondria and the cell danger response play into UC recovery - Oral glutathione vs injection—what's most effective? - Why peptides often work better than supplements for true cellular repair Our trusted telehealth partner: https://Elliemd.com/Carrotsncake Peptides for Women course: https://carrotsncake.com/offers/3Q7wttmr?coupon_code=PROTOCOL19 Free Training: Hormone-Driven Fat Loss Method: https://carrotsncake.kit.com/5909f18b13 Connect with Tina Haupert: https://carrotsncake.com/ Facebook: Carrots 'N' Cake https://www.facebook.com/carrotsncake Instagram: carrotsncake https://www.instagram.com/carrotsncake YouTube: Tina Haupert https://www.youtube.com/user/carrotsncake About Tina Haupert: Tina Haupert is the owner of Carrots ‘N' Cake as well as a Certified Nutrition Coach and Functional Diagnostic Nutrition Practitioner (FDN-P). Tina and her team use functional testing and a personalized approach to nutrition to help women find balance within their diets while achieving their body composition goals. Connect with Curtis Gillespie Sayers: https://lifestylempowerment.ca/ Facebook: https://www.facebook.com/1lifeestyleempowerment/ Youtube: https://www.youtube.com/@curtisfunctionalhealthcoach Instagram: https://instagram.com/that.coach.curtis About Curtis Gillespie Sayers: From a young age I was in and out of the hospital suffering from health complications for as long as I can remember, breathing difficulties being the most apparent but as I grew older more serious issues began to come to light. I was diagnosed with an extremely severe case of sleep apnea, high blood pressure, high cholesterol, and a pre-diabetic status. At this time, I was also struggling with substance abuse, which would obviously contribute to my health complications, but most were from birth. After receiving the news from running tests, the doctors had informed me that I was lucky to be alive. My psychological health was greatly impacted by my physiological health, evoking feelings of anger, and negativity which caused me to constantly argue with people around me. This affected several of my relationships and was creating a miserable life. This lead me to seek out the help of a bodybuilding coach (not knowing a damn thing about health at the time). The main focus was “getting shredded,” not understanding how much internal health affects one's physique. Interestingly enough, shedding the weight had really helped with my sleep apnea, but still, quite a few health complications were present. At this time hunger was ignited in me to learn more. I became determined to solve what was going on in my body. I decided to acquire my first nutrition certification through the ISSA (International Sports Science Association).

Our guest this time is Aaron Wolpoff who has spent his professional career as a marketing strategist and consultant to help companies develop strategic brands and enhance their audience growth. He owns the marketing firm, Double Zebra. He tells us about the name and how his company has helped a number of large and small companies grow and better serve their clients.   Aaron grew up in the San Diego area. He describes himself as a curious person and he says he always has been such. He loves to ask questions. He says as a child he was somewhat quiet, but always wanted to know more. He received his Bachelor's degree in marketing from the University of California at San Diego. After working for a firm for some four and a half years he and his wife moved up to the bay area in Northern California where attended San Francisco State University and obtained a Master's degree in Business.   In addition to his day job functioning as a business advisor and strategist Aaron also hosts a podcast entitled, We Fixed it, You're Welcome. I had the honor to appear on his podcast to discuss Uber and some of its accessibility issues especially concerning access by blind persons who use guide dogs to Uber's fleet. His podcast is quite fascinating and one I hope you will follow.   Aaron provides us in this episode many business insights. We talk about a number of challenges and successes marketing has brought to the business arena. I hope you like what Aaron offers.     About the Guest:   Aaron Wolpoff is a seasoned marketing strategist and communications consultant with a track record of positioning companies, products, and thought leadership for maximum impact. Throughout his career, Aaron has been somewhat of a trendspotter, getting involved in early initiatives around online banking, SaaS, EVs, IoT, and now AI, His ability to bridge complex industry dynamics and technology-driven solutions underscores his role as a forward-thinking consultant, podcaster, and business advisor, committed to enhancing organizational effectiveness and fostering strategic growth.   As the driving force behind the Double Zebra marketing company, Aaron excels in identifying untapped marketing assets, refining brand narratives, and orchestrating strategic pivots from paid advertising to organic audience growth. His insights have guided notable campaigns for consumer brands, technology firms, and professional service providers, always with a keen eye for differentiating messages that resonate deeply with target audiences. In addition to his strategic marketing expertise, Aaron hosts the Top 20 business management podcast, We Fixed It, You're Welcome, known for its sharp, humorous analysis of major corporate challenges and missteps. Each episode brings listeners inside complex business scenarios, unfolding like real-time case studies where Aaron and his panel of experts dissect high-profile decisions, offering insightful and actionable solutions. His ability to distill complex business issues into relatable, engaging discussions has garnered widespread acclaim and a dedicated following among executives and decision-makers.   Ways to connect with Aaron:   Marketing company: https://doublezebra.com Podcast: https://wefixeditpod.com LinkedIn: https://linkedin.com/in/marketingaaron     About the Host:   Michael Hingson is a New York Times best-selling author, international lecturer, and Chief Vision Officer for accessiBe. Michael, blind since birth, survived the 9/11 attacks with the help of his guide dog Roselle. This story is the subject of his best-selling book, Thunder Dog.   Michael gives over 100 presentations around the world each year speaking to influential groups such as Exxon Mobile, AT&T, Federal Express, Scripps College, Rutgers University, Children's Hospital, and the American Red Cross just to name a few. He is Ambassador for the National Braille Literacy Campaign for the National Federation of the Blind and also serves as Ambassador for the American Humane Association's 2012 Hero Dog Awards.   https://michaelhingson.com https://www.facebook.com/michael.hingson.author.speaker/ https://twitter.com/mhingson https://www.youtube.com/user/mhingson https://www.linkedin.com/in/michaelhingson/   accessiBe Links https://accessibe.com/ https://www.youtube.com/c/accessiBe https://www.linkedin.com/company/accessibe/mycompany/ https://www.facebook.com/accessibe/       Thanks for listening!   Thanks so much for listening to our podcast! If you enjoyed this episode and think that others could benefit from listening, please share it using the social media buttons on this page. Do you have some feedback or questions about this episode? Leave a comment in the section below!   Subscribe to the podcast   If you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on Apple Podcasts or Stitcher. You can subscribe in your favorite podcast app. You can also support our podcast through our tip jar https://tips.pinecast.com/jar/unstoppable-mindset .   Leave us an Apple Podcasts review   Ratings and reviews from our listeners are extremely valuable to us and greatly appreciated. They help our podcast rank higher on Apple Podcasts, which exposes our show to more awesome listeners like you. If you have a minute, please leave an honest review on Apple Podcasts.       Transcription Notes:   Michael Hingson ** 00:00 Access Cast and accessiBe Initiative presents Unstoppable Mindset. The podcast where inclusion, diversity and the unexpected meet. Hi, I'm Michael Hingson, Chief Vision Officer for accessiBe and the author of the number one New York Times bestselling book, Thunder dog, the story of a blind man, his guide dog and the triumph of trust. Thanks for joining me on my podcast as we explore our own blinding fears of inclusion unacceptance and our resistance to change. We will discover the idea that no matter the situation, or the people we encounter, our own fears, and prejudices often are our strongest barriers to moving forward. The unstoppable mindset podcast is sponsored by accessiBe, that's a c c e s s i capital B e. Visit www.accessibe.com to learn how you can make your website accessible for persons with disabilities. And to help make the internet fully inclusive by the year 2025. Glad you dropped by we're happy to meet you and to have you here with us.   Michael Hingson ** 01:20 Hi there, and welcome to another episode of unstoppable mindset. Today, we get to chat with Aaron Wolpoff, who is a marketing strategist and expert in a lot of different ways. I've read his bio, which you can find in the show notes. It seems to me that he is every bit as much of an expert is his bio says he is, but we're going to find out over the next hour or so for sure. We'll we'll not pick on him too much, but, but nevertheless, it's fun to be here. Aaron, so I want to welcome you to unstoppable mindset. I'm glad you're here, and we're glad that we get a chance to do   Aaron Wolpoff, ** 01:58 this. Thanks, Michael, thanks for having me. You're gonna grill me for an hour, huh?   Michael Hingson ** 02:04 Oh, sure. Why not? You're used to it. You're a marketing expert.   Aaron Wolpoff, ** 02:08 That's what we do. Yeah, we're always, uh, scrutiny for one thing or another.   Michael Hingson ** 02:13 I remember, I think it was back in was it 82 or 1982 or 1984 when they had the big Tylenol incident. You remember that? You know about   Aaron Wolpoff, ** 02:25 that? I do? Yeah, there's a Netflix documentary happening right now. Is there? Well, yeah,   Michael Hingson ** 02:31 a bottle of Tylenol was, for those who don't know, contaminated and someone died from it. But the manufacturer of Tylenol, the CEO the next day, just got right out in front of it and said what they were going to do about removing all Tylenol from the shelves until it could be they could all be examined and so on. Just did a number of things. It was a wonderful case, it seemed to me, for how to deal with a crisis when it came up. And I find that all too many companies and organizations don't necessarily know how to do that. Do they now?   Aaron Wolpoff, ** 03:09 And a lot of times they operate in crisis mode. That's the default. And no one likes to be around that, you know. So that's, I guess, step one is dealing even you know, deal with a crisis when it comes up, and make sure that your your day to day is not crisis fire as much as possible,   Michael Hingson ** 03:26 but know how to deal with a crisis, which is kind of the issue, and that's, that's what business continuity, of course, is, is really all about. I spoke at the Business Continuity Institute hybrid conference in London last October, and as one of the people who asked me to come and speak, explained, business continuity, people are the what if people that are always looking at, how do we deal with any kind of an emergency that comes up in an organization, knowing full well that nobody's really going to listen to them until there's really an emergency, and then, of course, they're indispensable, but The rest of the time they're not for   Aaron Wolpoff, ** 04:02 sure. Yeah, it's definitely that, you know, good. You bring up a good point about knowing how to deal with a crisis, because it will, it, will you run a business for long enough you have a company, no matter how big, eventually something bad is going to happen, and it's Tylenol. Was, is pre internet or, you know, we oh, yeah, good while ago they had time to formulate a response and craft it and and do a well presented, you know, public reassurance nowadays it's you'd have five seconds before you have to get something out there.   Michael Hingson ** 04:35 Well, even so, the CEO did it within, like, a day or so, just immediately came out and said what, what was initially going to be done. Of course, there was a whole lot more to it, but still, he got right out in front of it and dealt with it in a calm way, which I think is really important for businesses to do, and and I do find that so many don't and they they deal with so many different kinds of stress. Horrible things in the world, and they create more than they really should about fear anyway,   Aaron Wolpoff, ** 05:07 yeah, for sure, and now I think that Tylenol wasn't ultimately responsible. I haven't watched to the end, but if I remember correctly, but sometimes these crisis, crises that companies find themselves embroiled in, are self perpetuated? Yeah?   Michael Hingson ** 05:23 Well, Tylenol wasn't responsible. Somebody did it. Somebody put what, cyanide or something in into a Tylenol bottle. So they weren't responsible, but they sure dealt with it, which is the important thing. And you know, they're, they're still with us. Yeah?   Aaron Wolpoff, ** 05:38 No, they dealt with it. Well, their sales are great, everyday household product. No one can dispute it. But what I say is, with the with the instantaneousness of reach to your to your public, and to you know, consumers and public at large, a lot of crises are, can be self perpetuated, like you tweet the wrong thing, or is it called a tweet anymore? I don't know, but you know, you post something a little bit a little bit out of step with what people are think about you or thinking in general, and and now, all of a sudden, you're in the middle of something that you didn't want to be in the middle of, as a company well,   Michael Hingson ** 06:15 and I also noticed that, like the media will, so often they hear something, they report it, and they haven't necessarily checked to see the facts behind it, only to find out within an hour or two that what they reported was wrong. And they helped to sometimes promote the fear and promote the uncertainty, rather than waiting a little bit until they get all the information reasonably correct. And of course, part of the problem is they say, well, but everybody else is going to report it. So each station says everybody else is going to report it, so we have to keep up. Well, I'm not so sure about that all the time. Oh, that's very true, too, Michael, especially with, you know, off brand media outlets I'll spend with AI like, I'll be halfway through an article now, and I'll see something that's extremely generated and and I'll realize I've just wasted a whole bunch of time on a, you know, on a fake article, yeah, yeah, yeah, way, way too much. But even the mainstream media will report things very quickly to get it out there, but they don't necessarily have all the data, right. And I understand you can't wait for days to deal with things, but you should wait at least a little bit to make sure you've got data enough to report in a cogent way. And it just doesn't always happen.   Aaron Wolpoff, ** 07:33 Yeah, well, I don't know who the watch keepers of that are. I'm not a conspiracy theorist in that way by any means?   Michael Hingson ** 07:41 No, no, it isn't a conspiracy. But yeah,   Aaron Wolpoff, ** 07:44 yeah, no, no, I know, but it's again. I think it goes back to that tight the shortness of the cycle, like again. Tylenol waited a day to respond back in the day, which is great. But now, would you have you know, if Tylenol didn't say   Michael Hingson ** 07:59 anything for a day. If they were faced with a similar situation, people would vilify them and say, Well, wait, you waited a day to tell us something we wanted it in the first 30 seconds, yeah, oh, yeah. And that makes it more difficult, but I would hope that Tylenol would say, yeah. We waited a day because we were getting our facts together. 30 seconds is great in the media, but that doesn't work for reality, and in most cases, it doesn't. But yeah, I know what you're saying,   Aaron Wolpoff, ** 08:30 Yeah, but the appetite in the 24 hour news cycle, if people are hungry for new more information, so it does push news outlets, media outlets into let's respond as quick as possible and figure out the facts along the way. Yeah, yeah.   Michael Hingson ** 08:46 Well, for fun, why don't you tell us about sort of the early era and growing up, and how you got to doing the sorts of things that you're doing now. Well, I grew up in San Diego, California. I best weather in the country. I don't care what anyone says, Yeah,   Aaron Wolpoff, ** 09:03 you can't really beat it. No, I don't think anyone's gonna debate you on it. They call it the sunshine tax, because things cost a lot out here, but they do, you know, he grew up here, you put up with it. But yeah, so I grew up, grew up San Diego, college, San Diego. Life in San Diego, I've been elsewhere. I've traveled. I've seen some of the world. I like it. I've always wanted to come back, but I grew up really curious. I read a lot, I asked a lot of questions. And I also wanted, wanting to know, well, I want to know. Well, I wanted to know a lot of things about a lot of things, and I also was really scared. Is the wrong word, but I looked up to adults when I was a kid, and I didn't want to be put in a position where I was expected to know something that I didn't know. So it led to times where I'd pretend like I need you. Know, do you know? You know what this is, right? And I'd pretend like I knew, and early career, career even, and then I get called out on something, and it just was like a gut punch, like, but I'm supposed to know that, you know,   Michael Hingson ** 10:13 what did your parents think of you being so curious as you were growing up?   Aaron Wolpoff, ** 10:17 They they liked it, but I was quiet, okay? Quiet, quiet, quietly, confident and curious. It's just an interesting, I guess, an interesting mix. Yeah, but no, they Oh, they indulged it. I, you know, they answered my questions. They like I said, I read a lot, so frequent trips to the library to read a lot about a lot of things, but I think, you know, professionally, you take something that's kind of a grab bag, and what do I do with all these different interests? And when I started college undeclared, I realized, you know, communications, marketing, you kind of can make a discipline out of a bunch of interests, and call it something professional. Where did you go to college? I went to UCSD. UCSD, here in San Diego, yeah,   Michael Hingson ** 11:12 well, I was just up the road from you at UC Irvine. So here two good campuses,   Aaron Wolpoff, ** 11:18 they are, they are and UCSD. I was back recently. It's like a it's like a city. Now, every time we go back, we see these, these kids. They're babies. They get they get food every you know, they have, like, a food nice food court. There's parking, an abundance of parking, there's theaters, there's all the things we didn't have. Of course, we had some of it, but they just have, like, what if we had one of something or 50 parking spaces, they've got 5000 you know. And if we had, you know, one one food option, they got 35 Yeah, they don't know how good they have it.   Michael Hingson ** 11:53 When I was at UC urban, I think we had 3200 undergraduates. It wasn't huge. It was in that area. Now, I think there's 31,000 or 32,000 undergrads. Oh, wow. And as one of my former physics professors joked, he's retired, but I got to meet him. I was there, and last year I was inducted as an alumni member of Phi, beta, kappa. And so we were talking, and he said, You know what UCI really stands for, don't you? Well, I didn't, I said, What? And he said, under construction indefinitely. And there's, they're always building, sure, and that's that started when I was there, but, but they are always building. And it's just an amazing place today, with so many students and graduate students, undergrads and faculty, and it's, it's an amazing place. I think I'd have a little bit more of a challenge of learning where everything is, although I could do it, if I had to go back, I could do it. Yeah, UCI is nice. But I think you could say, you could say that about any of the UCs are constantly under, under development. And, you know, that's the old one. That's the old area. And I'm like, oh, that's I went to school in the old area. I know the old area. I remember Central Park. Yeah, for sure. Yeah. So you ended up majoring in Marketing and Communications,   Aaron Wolpoff, ** 13:15 yeah. So I undergrad in communications. They have a really nice business school now that they did not have at the time. So I predated that, but I probably would have ended up there. I got out with a very, not knocking the school. It's a great, wonderful school. I got out with a very theory, theoretical based degree. So I knew a lot about communications from a theory based perspective. I knew about brain cognition. I took maybe one quarter of practical use it professionally. It was like a video, like a video production course, so I I learned hands on, 111, quarter out of my entire academic career. But a lot of it was learning. The learning not necessarily applied, but just a lot of theory. And I started school at 17, and I got out just shortly after my 21st birthday, so I don't know what my hurry was, but, but there I was with a lot of theory, some some internships, but not a ton of professional experience. And, you know, trying to figure it out in the work world at that point. Did you get a graduate degree or just undergrad? I did. I went back. So I did it for almost five years in in financial marketing, and then, and I wear a suit and tie to work every day, which I don't think anyone does anymore. And I'm suddenly like, like, I'm from the 30s. I'm not that old, but, but no, seriously, we, you know, to work at the at the headquarters of a international credit union. Of course, I wear a suit, no after four and a half. Years there, I went back to graduate school up in the bay the Bay Area, Bay Area, and that's when I got my masters in in marketing. Oh, where'd you go in the Bay Area? San Francisco, state. Okay, okay, yeah, really nice school. It's got one of the biggest International MBA programs in the country, I think. And got to live in that city for a couple years.   Michael Hingson ** 15:24 We lived in Novato, so North Bay, for 12 years, from 2002 to the end of June 2014 Yeah, I like that area. That's, that's the, oh, the weather isn't San Diego's. That area is still a really nice area to live as well. Again, it is pretty expensive, but still it   Aaron Wolpoff, ** 15:44 is, yeah, I it's not San Diego weather, a beautiful day. There is like nothing else. But when we first got there, I said, I want to live by the beach. That's what I know. And we got out to the beach, which is like at the end of the outer sunset, and it's in the 40s streets, and it feels like the end of the universe. It just, it just like, feels apocalyptic. And I said, I don't want to live by the beach anymore, but, but no, it was. It was a great, great learning experience, getting an MBA. I always say it's kind of like a backpack or a toolkit you walk around with, because it is all that's all application. You know, everything that I learned about theory put into practice, you got to put into practice. And so I was, I was really glad that I that I got to do that. And like I said, Live, live in, live in the Bay. For a couple years, I'd always wanted   Michael Hingson ** 16:36 to, yeah, well, that's a nice area to live. If you got to live somewhere that is one of the nicer places. So glad you got that opportunity. And having done it, as I said for 12 years, I appreciate it too. And yeah, so much to offer there.   Aaron Wolpoff, ** 16:51 The only problem I had was it was in between the two.com bubbles. So literally, nothing was happening. The good side was that the apartment I was living in went for something like $5,500 before I got there, and then the draw everything dropped, you know, the bottom dropped out, and I was able to squeak by and afford living in the city. But, you know, you go for look, seeking your fortune. And there's, there's, I had just missed it. And then I left, and then it just came back. So I was, I was there during a lull. So you're the one, huh? Okay, I didn't do it, just the way Miami worked out. Did you then go back to San Diego? I did, yeah. So I've met my wife here. We moved up to the bay together, and when we were debating, when I graduated, we were thinking, do we want to drive, you know, an hour and a half Silicon Valley or someone, you know, somewhere further out just to stay in the area? Or do we want to go back to where we where we know and like, and start a life there and we, you know, send, like you said at the beginning, San Diego is not a bad place to be. So as it was never a fallback, but as a place to, you know, come back home to, yeah, I welcomed it.   Michael Hingson ** 18:08 And so what did you do when you came back to San Diego?   Aaron Wolpoff, ** 18:12 So I have my best friend from childhood was starting as a photography company still does, and it was starting like a sister company, as an agency to serve the photography company, which was growing really fast, and then also, like picking up clients and building a book out of so he said, you know you're, I see you're applying for jobs, and I know that you're, you know, you're getting some offers and things, but just say no To all of them and come work with me and and at the time it was, it was running out of a was like a loft of an apartment, but it, you know, it grew to us, a small staff, and then a bigger staff, and spun off on its own. And so that's, that's what I did right out of, right out of grad school. I said no to a few things, and said there's a lot, lot worse fates than you know, spending your work day with your best friend and and growing a company out and so what exactly did you do for them? So it was like, we'll call it a boutique creative agency. It was around the time of I'm making myself sound so old. See, so there was flash, flash technology, like web banners were made with Flash. It had moved to be flash, Adobe, Flash, yeah. So companies were making these web banners, and what you call interactive we got a proficiency of making full website experiences with Flash, which not a lot of companies were doing. So because of that, it led to some really interesting opportunities and clients and being able to take on a capability, a proficiency that you know for a time. Uh was, was uh as a differentiator, say, you know, you could have a web banner and an old website, or you could have a flash, interactive website where you take your users on an experience with music and all the things that seem so dated now,   Michael Hingson ** 20:14 well, and of course, unfortunately, a lot of that content wasn't very accessible, so some of us didn't really get access to a lot of it, and I don't remember whether Adobe really worked to make flash all that accessible. They dealt with other things, but I'm not sure that flash ever really was. Yeah, I'm with you on that. I really, I don't think so.   Aaron Wolpoff, ** 20:38 What we would wind up doing is making parallel websites, but, but then mobile became a thing, and then you'd make a third version of a website, and it just got tedious. And really it's when the iPhone came out. It just it flash got stopped in its tracks, like it was like a week, and then action script, which is the language that it runs on, and all the all the capabilities and proficiencies, just there was no use for it anymore.   Michael Hingson ** 21:07 Well, and and the iPhone came out, as you said, and one of the things that happened fairly early on was that, because they were going to be sued, Apple agreed to make the I devices accessible, and they did something that hadn't really been done up to that time. They set the trend for it. They built accessibility into the operating systems, and they built the ability to have accessibility into the operating systems. The one thing that I wish that Apple would do even a little bit more of than they do, than they do today, although it's better than it used to be, is I wish they would mandate, or require people who are going to put apps in the App Store, for example, to make sure that the apps are accessible. They have guidelines. They have all sorts of information about how to do it, but they don't really require it, and so you can still get inaccessible apps, which is unfortunate,   Aaron Wolpoff, ** 22:09 that is Yeah, and like you said, with Flash, an entire you know, ecosystem had limited to no accessibility, so   Michael Hingson ** 22:16 and making additional on another website, Yeah, a lot of places did that, but they weren't totally equal, because they would make enough of the website, well, they would make the website have enough content to be able to do things, but they didn't have everything that they had on the graphical or flash website, and so It was definitely there, but it wasn't really, truly equal, which is unfortunate, and so now it's a lot better.   Aaron Wolpoff, ** 22:46 Yeah, it is no and I hate to say it, but if it came down to limited time, limited budget, limited everything you want to make something that is usable and efficient, but no, I mean, I can't speak for all developers, but no, it would be hard. You'd be hard pressed to create a an equally parallel experience with full accessibility at the time.   Michael Hingson ** 23:16 Yeah, yeah, you would. And it is a lot better. And there's, there's still stuff that needs to be done, but I think over time, AI is going to help some of that. And it is already made. It isn't perfect yet, but even some graphics and so on can be described by AI. And we're seeing things improve over, over, kind of what they were. So we're making progress, which is good,   Aaron Wolpoff, ** 23:44 yeah, no, I'm really happy about that. And with with AI and AI can go through and parse your code and build in all you know, everything that that needs to happen, there's a lot less excuse for for not making something as accessible as it can   Michael Hingson ** 23:59 be, yeah, but people still ignore it to a large degree. Still, only about 3% of all websites really have taken the time to put some level of accessibility into them. So there's still a lot to be done, and it's just not that magical or that hard, but it's mostly, I think, education. People don't know, they don't know that it can be done. They don't think about it being done, or they don't do it initially, and so then it becomes a lot more expensive to do later on, because you got to go back and redo   Aaron Wolpoff, ** 24:28 it, all right, yeah, anything, anytime you have to do something, something retroactive or rebuild, you're, yeah, you're starting from not a great place.   Michael Hingson ** 24:37 So how long did you work with your friend?   Aaron Wolpoff, ** 24:42 A really long time, because I did the studio, and then I wound up keeping that alive. But going over to the photography side, the company really grew. Had a team of staff photographers, had a team of, like a network of photographers, and. And was doing quite, quite a lot, an abundance of events every year, weddings and corporate and all types of things. So all in, I was with the company till, gosh, I want to say, like, 2014 or so. Wow. Yeah. Yeah.   Michael Hingson ** 25:21 And then what did you go off and do?   Aaron Wolpoff, ** 25:25 So then I worked for an agency, so I got started with creative and, well, rewinding, I got started with financial marketing, with the suit and tie. But then I went into creative, and I've tried pretty much every aspect of marketing I hadn't done marketing automation and email sequences and CRMs and outreach and those types of things. So that was the agency I worked for that was their specialization, which I like, to a degree, but it's, it's not my, not my home base. Yeah, there's, there's people that love and breathe automation. I like having interjecting some, you know, some type of personal aspect into the what you're putting out there. And I have to wrestle with that as ai, ai keeps growing in prominence, like, Where's the place for the human, creative? But I did that for a little while, and then I've been on my own for the past six or seven years.   Michael Hingson ** 26:26 So what is it you do today? Exactly?   Aaron Wolpoff, ** 26:30 So I'm, we'll call it a fractional CMO, or a fractional marketing advisor. So I come in and help companies grow their their marketing and figure themselves out. I've gone I work with large companies. I've kind of gone back to early stage startups and and tech companies. I just find that they're doing really more, a lot more interesting things right now with the market the way it is. They're taking more chances and and they're they're moving faster. I like to move pretty quick, so that's where my head's at. And I'm doing more. We'll call em like CO entrepreneurial ventures with my clients, as opposed to just a pure agency service model, which is interesting. And and I got my own podcast. There you go. Yeah. What's your podcast called? Not to keep you busy, it's called, we fixed it. You're welcome. There you   Michael Hingson ** 27:25 go. And it seems to me, if my memory hasn't failed me, even though I don't take one of those memory or brain supplements, we were on it not too long ago, talking about Uber, which was fun.   Aaron Wolpoff, ** 27:39 We had you on there. I don't know which episode will drop first, this one or or the one you were on, but we sure enjoyed having you on there.   Michael Hingson ** 27:46 Well, it was fun. Well, we'll have to do more of it, and I think it'd be fun to but so you own your own business. Then today,   Aaron Wolpoff, ** 27:53 I do, yeah, it's called Double zebra.   Michael Hingson ** 27:56 Now, how did you come up with that name?   Aaron Wolpoff, ** 27:59 It's two basic elements, so basic, black and white, something unremarkable, but if you can take it and multiply it or repeat it, then you're onto something interesting.   Michael Hingson ** 28:13 Lots of stripes. Yeah, lots of stripes.   Aaron Wolpoff, ** 28:17 And it's always fun when I talk to someone in the UK or Australia, or then they say zebra or zebra, right? I get to hear the way they say it. It's that's fun. Occasionally I get double double zero. People will miss misname it and double zero. That's his   Michael Hingson ** 28:34 company's that. But has anybody called it double Zed yet?   Aaron Wolpoff, ** 28:39 No, that's a new one.   Michael Hingson ** 28:41 Yeah? Well, you never know. Maybe we've given somebody the idea now. Yeah, yeah. Well, so I'm I'm curious. You obviously do a lot to analyze and help people in critique in corporate mishaps. Have you ever seen a particular business mistake that you really admire and just really love, its audacity,   Aaron Wolpoff, ** 29:07 where it came out wrong, but I liked it anyway, yeah, oh, man,   Michael Hingson ** 29:13 let's see, or one maybe, where they learned from their mistake and fixed it. But still, yeah, sure.   Aaron Wolpoff, ** 29:23 Yeah, that's a good one. I like, I like bold moves, even if they're wrong, as long as they don't, you know, they're not harmful to people I don't know. Let's go. I'm I'm making myself old. Let's go back to Crystal crystal. Pepsi, there you go for that. But that was just such a fun idea at the time. You know, we're the new generation and, and this is the 90s, and everything's new now, and we're going to take the color out of out of soda, I know we're and we're going to take it and just make it what you know, but a little unfamiliar, right? Right? It's Crystal Pepsi, and the ads were cool, and it was just very of the moment. Now, that moment didn't last very long, no, and the public didn't, didn't hold on to it very long. But there's, you know, it was, it let you question, and I in a good way, what you thought about what is even a Pepsi. And it worked. It was they brought it back, like for a very short time, five, I want to say five or six years ago, just because people had a nostalgia for it. But yeah, big, big, bold, we're confident this is the new everyone's going to be talking about this for a long time, and we're going to put a huge budget behind it, Crystal Pepsi. And it it didn't, but yeah, I liked it.   Michael Hingson ** 30:45 So why is that that is clearly somebody had to put a lot of effort into the concept, and must have gotten some sort of message that it would be very successful, but then it wasn't,   Aaron Wolpoff, ** 31:00 yeah, yeah. For something like that, you have to get buy in at so many levels. You know, you have an agency saying, this is the right thing to do. You have CD, your leadership saying, No, I don't know. Let's pull back. Whenever an agency gets away with something and and spends a bunch of client money and it's just audacious, and I can't believe they did it. I know how many levels of buy in they had to get, yeah, to say, Trust me. Trust me. And a lot of times it works, you know, if they do something that just no one else had had thought of or wasn't willing to do, and then you see that they got through all those levels of bureaucracy and they were able to pull it off.   Michael Hingson ** 31:39 When it works. I love it. When it doesn't work. I love it, you know, just, just the fact that they did it, yeah, you got to admire that. Gotta admire it. They pulled it off, yeah. My favorite is still ranch flavored Fritos. They disappeared, and I've never understood why I love ranch flavored Fritos. And we had them in New Jersey and so on. And then we got, I think, out to California. But by that time, they had started to fade away, and I still have never understood why. Since people love ranch food so   Aaron Wolpoff, ** 32:06 much, that's a good one. I don't know that. I know those because it does, it does that one actually fill a market need. If there's Doritos, there's, you know, the ranch, I don't know if they were, they different.   Michael Hingson ** 32:17 They were Fritos, but they they did have ranch you know they were, they were ranch flavored, and I thought they were great. Yeah, I don't know. I don't know that one didn't hit because they have, I think they have chili flavor. They have regular. Do they have anything else honey barbecue? I don't know. I don't know, but I do still like regular, but I love ranch flavored the best. Now, I heard last week that Honey Nut Cheerios are going away. General Mills is getting rid of honey nut cheerios. No, is that real? That's what I heard on the news. Okay, I believe you, but I'll look it up anyway. Well, it's interesting. I don't know why, after so many years, they would but there have been other examples of cereals and so on that were around for a while and left and, well, Captain Crunch was Captain Crunch was one, and I'm not sure if lucky charms are still around. And then there was one called twinkles.   Aaron Wolpoff, ** 33:13 And I know all those except twinkles, but I would if you asked me, I would say, Honey Nut Cheerios. There's I would say their sales are better than Cheerios, or at least I would think so, yeah, at least a good portfolio company. Well, who knows, who knows, but I do know that Gen Z and millennials eat cereal a lot less than us older folks, because it takes work to put milk and cereal into a bowl, and it's not pre made, yeah. So maybe it's got to do with, you know, changing eating habits and consumer preferences   Michael Hingson ** 33:48 must be Yeah, and they're not enough of us, older, more experienced people to to counteract that. But you know, well, we'll see Yeah, as long as they don't get rid of the formula because it may come back. Yeah, well, now   Aaron Wolpoff, ** 34:03 Yeah, exactly between nostalgia and reboots and remakes and nothing's gone forever, everything comes back eventually.   Michael Hingson ** 34:10 Yeah, it does in all the work that you've done. Have you ever had to completely rethink and remake your approach and do something different?   Aaron Wolpoff, ** 34:24 Yeah, well, there's been times where I've been on uncharted territory. I worked with an EV company before EVs were a thing, and it was going, actually going head to head with with Tesla. But the thing there's they keep trying to bring it back and crowd sourcing it and all that stuff. It's, but at the time, it was like, I said it was like, which is gonna make it first this company, or Tesla, but, but this one looks like a, it looks, it feels like a spaceship. It's got, like space. It's a, it's, it's really. Be really unique. So the one that that is more like a family car one out probably rightly so. But there was no consumer understanding of not, let alone our preference, like there is now for an EV and what do I do? I have to plug it in somewhere and and all those things. So I had to rethink, you know what? There's no playbook for that yet. I guess I have to kind of work on it. And they were only in prototyping at the point where we came in and had to launch this, you know, teaser and teaser campaign for it, and build up awareness and demand for this thing that existed on a computer at the time.   Michael Hingson ** 35:43 What? Why is Tesla so successful?   Aaron Wolpoff, ** 35:48 Because they spent a bunch of money. Okay, that helps? Yeah, they were playing the long game. They could outspend competitors. They've got the unique distribution model. And they kind of like, I said, retrained consumers into how you buy a car, why you buy a car, and, and I think politics aside, people love their people love their teslas. You don't. My understanding is you don't have to do a whole lot once you buy it. And, and they they, like I said, they had the money to throw at it, that they could wait, wait it out and wait out that when you do anything with retraining consumers or behavior change or telling them you know, your old car is bad, your new this new one's good, that's the most. We'll call it costly and and difficult forms of marketing is retraining behavior. But they, they had the money to write it out and and their products great, you know, again, I'm not a Tesla enthusiast, but it's, it looks good. People love it. I you know, they run great from everything that I know, but so did a lot of other companies. So I think they just had the confidence in what they were doing to throw money at it and wait, be patient and well,   Michael Hingson ** 37:19 they're around there again the the Tesla is another example of not nearly as accessible as it should be and and I recognize that I'm not going to be the primary driver of a Tesla today, although I have driven a Tesla down Interstate 15, about 15 miles the driver was in the car, but, but I did it for about 15 miles going down I 15 and fully appreciate what autonomous vehicles will be able to do. We're way too much still on the cusp, and I think that people who just poo poo them are missing it. But I also know we're not there yet, but the day is going to come when there's going to be a lot more reliability, a lot less potential for accidents. But the thing that I find, like with the Tesla from a passenger standpoint, is I can't do any of the things that a that a sighted passenger can do. I can't unless it's changed in the last couple of years. I can't manipulate the radio. I can't do the other things that that that passengers might do in the Tesla, and I should be able to do that, and of all the vehicles where they ought to have access and could, the Tesla would be one, and they could do it even still using touch screens. I mean, the iPhone, for example, is all touch screen. But Apple was very creative about creating a mechanism to allow a person to not need to look at the screen using VoiceOver, the screen reader on the iPhone, but having a new set of gestures that were created that work with VoiceOver so that I could interact with that screen just as well as you can.   Aaron Wolpoff, ** 38:59 That's interesting that you say that, you know, Apple was working on a car for a while, and I don't know to a fact, but I bet they were thinking through accessibility and building that into every turn, or at least planning to,   Michael Hingson ** 39:13 oh, I'm sure they were. And the reality is, it isn't again. It isn't that magical to do. It would be simple for the Teslas and and other vehicles to do it. But, you know, we're we're not there mentally. And that's of course, the whole issue is that we just societally don't tend to really look at accessibility like we should. My view of of, say, the apple the iPhone, still is that they could be marketing the screen reader software that I use, which is built into the system already. They could, they could do some things to mark market that a whole lot more than they already do for sighted people. Your iPhone rings, um. You have to tap it a lot of times to be able to answer it. Why can't they create a mode when you're in a vehicle where a lot more of that is verbally, spoken and handled through voice output from the phone and voice input from you, without ever having to look at or interact with the screen.   Aaron Wolpoff, ** 40:19 I bet you're right, yeah, it's just another app at that point   Michael Hingson ** 40:22 well, and it's what I do. I mean, it's the way I operate with it. So I just think that they could, they could be more creative. There's so many examples of things that begin in one way and alter themselves or become altered. The typewriter, for example, was originally developed for a blind Countess to be able to communicate with her lover without her husband finding out her husband wasn't very attentive to her anyway. But the point is that the, I think the lover, created the this device where she could actually sit down and type a letter and seal it and give it to a maid or someone to give to, to her, her friend. And that's how the typewriter other other people had created, some examples, but the typewriter from her was probably the thing that most led to what we have today.   Aaron Wolpoff, ** 41:17 Oh, I didn't know that. But let me Michael, let me ask you. So I was in LA not too long ago, and they have, you know, driverless vehicles are not the form yet, but they we, I saw them around the city. What do you think about driverless vehicles in terms of accessibility or otherwise?   Michael Hingson ** 41:32 Well, again, so, so the most basic challenge that, fortunately, they haven't really pushed which is great, is okay, you're driving along in an autonomous vehicle and you lose connection, or whatever. How are you going to be able to pull it off to the side of the road? Now, some people have talked about saying that there, there has to be a law that only sighted people could well the sighted people a sighted person has to be in the vehicle. The reality is, the technology has already been developed to allow a blind person to get behind the wheel of a car and have enough information to be able to drive that vehicle just as well, or nearly as well, as a sighted person. But I think for this, from the standpoint of autonomousness, I'm all for it. I think we're going to continue to see it. It's going to continue to get better. It is getting better daily. So I haven't ridden in a fully autonomous vehicle, but I do believe that that those vehicles need to make sure, or the manufacturers need to make sure that they really do put accessibility into it. I should be able to give the vehicle all the instructions and get all the information that any sighted person would get from the vehicle, and the technology absolutely exists to do that today. So I think we will continue to see that, and I think it will get better all the way around. I don't know whether, well, I think they that actually there have been examples of blind people who've gotten into an autonomous vehicle where there wasn't a sighted person, and they've been able to function with it pretty well. So I don't see why it should be a problem at all, and it's only going to get   Aaron Wolpoff, ** 43:22 better. Yeah, for sure. And I keep thinking, you know, accessibility would be a prior priority in autonomous vehicles, but I keep learning from you, you know you were on our show and and our discussions, that the priorities are not always in line and not always where they necessarily should   Michael Hingson ** 43:39 be. Well. And again, there are reasons for it, and while I might not like it, I understand it, and that is, a lot of it is education, and a lot of it is is awareness. Most schools that teach people how to code to develop websites don't spend a lot of time dealing with accessibility, even though putting all the codes in and creating accessible websites is not a magically difficult thing to do, but it's an awareness issue. And so yeah, we're just going to have to continue to fight the fight and work toward getting people to be more aware of why it's necessary. And in reality, I do believe that there is a lot of truth to this fact that making things more accessible for me will help other people as well, because by having not well, voice input, certainly in a vehicle, but voice output and so on, and a way for me to accessibly, be able to input information into an autonomous vehicle to take to have it take me where I want to go, is only going to help everyone else as well. A lot of things that I need would benefit sighted people so well, so much.   Aaron Wolpoff, ** 44:56 Yeah, you're exactly right. Yeah, AI assisted. And voice input and all those things, they are universally loved and accepted now, yeah,   Michael Hingson ** 45:07 it's getting better. The unemployment rate is still very high among, for example, employable blind people, because all too many people still think blind people can't work, even though they can. So it's all based on prejudice rather than reality, and we're, we're, we're just going to have to continue to work to try to deal with the issues. I wrote an article a couple of years ago. One of the things where we're constantly identified in the world is we're blind or visually impaired. And the problem with visually impaired is visually we're not different simply because we don't see and impaired, we are not we're getting people slowly to switch to blind and low vision, deaf people and hard of hearing people did that years ago. If you tell a deaf person they're hearing impaired, they're liable to deck you on the spot. Yeah, and blind people haven't progressed to that point, but it's getting there, and the reality is blind and low vision is a much more appropriate terminology to use, and it's not equating us to not having eyesight by saying we're impaired, you know. So it's it's an ongoing process, and all we can do is continue to work at it?   Aaron Wolpoff, ** 46:21 Yeah, no. And I appreciate that you do. Like I said, education and retraining is, is call it marketing or call it, you know, just the way people should behave. But it's, that's, it's hard. It's one of the hardest things to do.   Michael Hingson ** 46:36 But, you know, we're making progress, and we'll, we'll continue to do that, and I think over time we'll we'll see things improve. It may not happen as quickly as we'd like, but I also believe that I and other people who are blind do need to be educators. We need to teach people. We need to be patient enough to do that. And you know, I see so often articles written about Me who talk about how my guide dog led me out of the World Trade Center. The guide dog doesn't lead anybody anywhere. That's not the job of the dog. The dog's job is to make sure that we walk safely. It's my job to know where to go and how to get there. So a guide dog guides and will make sure that we walk safely. But I'm the one that has to tell the dog, step by step, where I want the dog to go, and that story is really the crux of what I talk about many times when I travel and speak to talk to the public about what happened in the World Trade Center, because I spent a lot of time learning what I needed to do in order to escape safely and on September 11, not ever Having anticipated that we would need that kind of information, but still preparing for it, the mindset kicked in, and it all worked well.   Aaron Wolpoff, ** 47:49 You You and I talked about Uber on on my show, when you came on, and we gave them a little ding and figured out some stuff for them, what in terms of accessibility, and, you know, just general corporate citizenship, what's what's a company that, let's give them a give, give, call them out for a good reason? What's a company that's doing a good job, in your eyes, in your mind, for accessibility, maybe an unexpected one.   Michael Hingson ** 48:20 Well, as I mentioned before, I think Apple is doing a lot of good things. I think Microsoft is doing some good I think they could do better than they are in in some ways, but they're working at it. I wish Google would put a little bit more emphasis on making its you its interface more more usable to you really use the like with Google Docs and so on. You have to hurt learn a whole lot of different commands to make part of that system work, rather than it being as straightforward as it should be, there's some new companies coming up. There's a new company called inno search. Inno search.ai, it was primarily designed at this point for blind and low vision people. The idea behind inner search is to have any a way of dealing with E commerce and getting people to be able to help get help shopping and so on. So they actually have a a phone number. It's, I think it's 855, shop, G, P, T, and you can go in, and you can talk to the bot and tell it what you want, and it can help fill up a shopping cart. It's using artificial intelligence, but it understands really well. I have yet to hear it tell me I don't understand what you want. Sometimes it gives me a lot of things that more than I than I'm searching for. So there, there's work that needs to be done, but in a search is really a very clever company that is spending a lot of time working to make. Sure that everything that it does to make a shopping experience enjoyable is also making sure that it's accessible.   Aaron Wolpoff, ** 50:08 Oh, that's really interesting. Now, with with my podcast, and just in general, I spend a lot of time critiquing companies and and not taking them to test, but figuring out how to make them better. But I always like the opportunity to say you did something well, like even quietly, or you're, you know, people are finding you because of a certain something you didn't you took it upon yourselves to do and figure out   Michael Hingson ** 50:34 there's an audio editor, and we use it some unstoppable mindset called Reaper. And Reaper is a really great digital audio workstation product. And there is a whole series of scripts that have been written that make Reaper incredibly accessible as an audio editing tool. It's really great. It's about one of the most accessible products that I think I have seen is because they've done so well with it, which is kind of cool.   Aaron Wolpoff, ** 51:06 Oh, very nice. Okay, good. It's not even expensive. You gave me two to look, to pay attention to, and, you know, Track, track, along with,   Michael Hingson ** 51:16 yeah, they're, they're, they're fun. So what do people assume about you that isn't true or that you don't think is true?   Aaron Wolpoff, ** 51:25 People say, I'm quiet at times, guess going back to childhood, but there's time, there's situation. It's it's situational. There's times where I don't have to be the loudest person in the room or or be the one to talk the most, I can hang back and observe, but I would not categorize myself as quiet, you know, like I said, it's environmental. But now I've got plenty to say. You just have to engage me, I guess.   Michael Hingson ** 51:56 Yeah, well, you know, it's interesting. I'm trying to remember   Michael Hingson ** 52:04 on Shark Tank, what's Mark's last name, Cuban. Cuban. It's interesting to watch Mark on Shark Tank. I don't know whether he's really a quiet person normally, but I see when I watch Shark Tank. The other guys, like Mr. Wonderful with Kevin are talking all the time, and Mark just sits back and doesn't say anything for the longest period of time, and then he drops a bomb and bids and wins. Right? He's just really clever about the way he does it. I think there's a lot to be said for not just having to speak up every single time, but rather really thinking things through. And he clearly does that,   Aaron Wolpoff, ** 52:46 yeah, yeah, you have to appreciate that. And I think that's part of the reason that you know, when I came time to do a podcast, I did a panel show, because I'm surrounded by bright, interesting, articulate people, you included as coming on with us and and I don't have to fill every second. I can, I can, I, you know, I can intake information and think for a second and then maybe have a   Michael Hingson ** 53:15 response. Well, I think that makes a lot of sense, doesn't it? I mean, it's the way it really ought to be.   Aaron Wolpoff, ** 53:20 Yeah, if you got to fill an hour by yourself, you're always on, right?   Michael Hingson ** 53:26 Yeah, I know exactly what you mean. I know when I travel to speak. I figure that when I land somewhere, I'm on until I leave again. So I always enjoy reading books, especially going and coming on airplanes. And then I can be on the whole time. I am wherever I have to be, and then when I get on the airplane to come home, I can relax again.   Aaron Wolpoff, ** 53:45 Now, I like that. And I know, you keynote, I think I'd rather moderate, you know, I'll say something when I have something to say, and let other people talk for a while. Well, you gotta, you have a great story, and you're, you know, I'm glad you're getting it out there.   Michael Hingson ** 53:58 Well, if anybody needs a keynote speaker. Just saying, for everybody listening, feel free to email me. I'd love to hear from you. You can email me at Michael H i@accessibe.com or speaker at Michael hingson.com always looking for speaking engagements. Then we got that one in. I'm glad, but, but you know, for you, is there a podcast episode that you haven't done, that you really want to do, that just seems to be eluding you?   Aaron Wolpoff, ** 54:28 There are a couple that got away. I wanted to do one about Sesame Street because it was without a it was looking like it was going to be without a home. And that's such a hallmark of my childhood. And so many, yeah, I think they worked out a deal, which is probably what I was going to propose with. It's like a CO production deal with Netflix. So it seems like they're safe for the foreseeable future. But what was the other I think there's, there's at least one or two more where maybe the guests didn't line up, or. Or the timeliness didn't work. I was going to have someone connected to Big Lots. You remember Big Lots? I think they're still around to some degree, but I think they are, come on and tell me their story, because they've, you know, they've been on the brink of extinction for a little while. So it's usually, it's either a timing thing, with the with with the guest, or the news cycle has just maybe gone on and moved past us.   Michael Hingson ** 55:28 But, yeah, I know people wrote off Red Lobster for a while, but they're still around.   Aaron Wolpoff, ** 55:35 They're still around. That would be a good one. Yeah, their endless shrimp didn't do them any favors. No, that didn't help a whole lot, but it's the companies, even the ones we've done already, you know, they they're still six months later. Toilet hasn't been even a full year of our show yet, but in a year, I bet there's, you know, we could revisit them all over again, and they're still going to find themselves in, I don't know, hot water, but some kind of controversy for one reason or another. And we'll, we'll try to help them out again.   Michael Hingson ** 56:06 Have you seen any successes from the podcast episodes where a company did listen to you and has made some changes?   Aaron Wolpoff, ** 56:15 I don't know that. I can correlate one to one. We know that they listen. We can look at the metrics and where the where the list listens, are coming from, especially with LinkedIn, gives you some engagement and tells you which companies are paying attention. So we know that they are and they have now, whether they took that and, you know, implemented it, we have a disclaimer saying, Don't do it. You know, we're not there to give you unfiltered legal advice. You know, don't hold us accountable for anything we say. But if we said something good and you like it, do it. So, you know, I don't know to a T if they have then we probably given away billions of dollars worth of fixes. But, you know, I don't know the correlation between those who have listened and those who have acted on something that we might have, you know, alluded to or set out, right? But it has. We've been the times that we take it really seriously. We've we've predicted some things that have come come to pass.   Michael Hingson ** 57:13 That's cool, yeah. Well, you certainly had a great career, and you've done a lot of interesting things. If you had to suddenly change careers and do something entirely different from what you're doing, what would it be?   Aaron Wolpoff, ** 57:26 Oh, man, my family laughs at me, but I think it would be a furniture salesman. There you go. Yeah, I don't know why. There's something about it's just enough repetition and just enough creativity. I guess, where people come in, you tell them, you know you, they tell you their story, you know, you get to know them. And then you say, Oh, well, this sofa would be amazing, you know, and not, not one with endless varieties, not one with with two models somewhere in between. Yeah, I think that would be it keeps you on your feet.   Michael Hingson ** 58:05 Furniture salesman, well, if you, you know, if you get too bored, math is homes and Bob's furniture probably looking for people.   Aaron Wolpoff, ** 58:12 Yeah, I could probably do that at night.   Michael Hingson ** 58:18 What advice do you give to people who are just starting out, or what kinds of things do you would you give to people we have ideas and thoughts?   Aaron Wolpoff, ** 58:27 So I've done a lot of mentoring. I've done a lot of one on one calls. They told I always work with an organization. They told me I did 100 plus calls. I always tell people to take use the create their own momentum, so you can apply for things, you can stand in line, you can wait, or you can come up with your own idea and test it out and say, I'm doing this. Who wants in? And the minute you have an idea, people are interested. You know, you're on to something. Let me see what that's all about. You know, I want to be one of the three that you're looking for. So I tell them, create their own momentum. Try to flip the power dynamic. So if you're asking for a job, how do you get the person that you're asking to want something from you and and do things that are take on, things that are within your control?   Michael Hingson ** 59:18 Right? Right? Well, if you had to go back and tell the younger Aaron something from years ago, what would you give him in the way of advice?   Aaron Wolpoff, ** 59:30 Be more vulnerable. Don't pretend you know everything. There you go. And you don't need to know everything. You need to know what you know. And then get a little better and get a little better.   Michael Hingson ** 59:43 One of the things that I constantly tell people who I hire as salespeople is you can be a student, at least for a year. Don't hesitate to ask your customers questions because they're not out to. Get you. They want you to succeed. And if you interact with your customers and you're willing to learn from them, they're willing to teach, and you'll learn so much that you never would have thought you would learn. I just think that's such a great concept.   Aaron Wolpoff, ** 1:00:12 Oh, exactly right. Yeah. As soon as I started saying that to clients, you know, they would throw out an industry term. As soon as I've said I don't know what that is, can you explain it to me? Yeah? And they did, and the world didn't fall apart. And I didn't, you know, didn't look like the idiot that I thought I would when we went on with our day. Yeah, that whole protective barrier that I worked so hard to keep up as a facade, I didn't have to do it, and it was so freeing. Yeah, yeah, yeah,   Michael Hingson ** 1:00:41 I hear you. Well, this has been fun. We've been doing it for an hour. Can you believe it? Oh, hey, that was a quick hour. I know it was a lot of fun. Well, I want to thank you for being here, and I want to thank you all for listening. Please give us a five star rating wherever you're listening or watching. We really appreciate it. We value your thoughts. I'd love to hear from you and get your thoughts on our episode today. And I'm sure Aaron would like that as well, and I'll give you an email address in a moment. But Aaron, if people want to reach out to you and maybe use your services, how do they do that?   Aaron Wolpoff, ** 1:01:12 Yeah, so two ways you can check me out, at double zebra, z, E, B, R, A, double zebra.com and the podcast, I encourage you to check out too. We fixed it. Pod.com, we fixed it.   Michael Hingson ** 1:01:25 Pod.com, there you go. So reach out to Aaron and get marketing stuff done and again. Thank you all. My email address, if you'd like to talk to us, is Michael, H, I m, I C, H, A, E, L, H, I at accessibe, A, C, C, E, S, S, i, b, e.com, and if you know anyone else who you think ought to be a guest on our podcast, we'd love it if you give us an introduction. We're always looking for people, so please do and again. Aaron, I just want to thank you for being here. This has been a lot of fun.   Aaron Wolpoff, ** 1:01:58 That was great. Thanks for having me. Michael,   **Michael Hingson ** 1:02:05 You have been listening to the Unstoppable Mindset podcast. Thanks for dropping by. I hope that you'll join us again next week, and in future weeks for upcoming episodes. To subscribe to our podcast and to learn about upcoming episodes, please visit www dot Michael hingson.com slash podcast. Michael Hingson is spelled m i c h a e l h i n g s o n. While you're on the site., please use the form there to recommend people who we ought to interview in upcoming editions of the show. And also, we ask you and urge you to invite your friends to join us in the future. If you know of any one or any organization needing a speaker for an event, please email me at speaker at Michael hingson.com. I appreciate it very much. To learn more about the concept of blinded by fear, please visit www dot Michael hingson.com forward slash blinded by fear and while you're there, feel free to pick up a copy of my free eBook entitled blinded by fear. The unstoppable mindset podcast is provided by access cast an initiative of accessiBe and is sponsored by accessiBe. Please visit www.accessibe.com . AccessiBe is spelled a c c e s s i b e. There you can learn all about how you can make your website inclusive for all persons with disabilities and how you can help make the internet fully inclusive by 2025. Thanks again for Listening. Please come back and visit us again next week.

Standard Japanese, Days Off, Being Japanese, + English & Japanese Subtitles for Learners 標準語、休日、日本人の定義など！ Today we talk about standard Japanese and its effect on the Japanese language and culture and whether it should still exist. Send us questions at:  lazyfluency@gmail.com Join the Community: Discord: https://discord.gg/VGSd94Tp4P Book Club! https://discord.com/channels/1204531163377442866/1402788543721508977 Support on ko-fi:  https://ko-fi.com/lazyfluency Follow us: Main channel:  https://www.youtube.com/channel/UC-8_djC5_aV4Mi3o3fuLPLA Instagram:https://www.instagram.com/lazyfluency/ Twitter: https://twitter.com/lazyfluency  

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

SUBSCRIBE to The One to Go Show presented by ImpactHealth SharingSoil & Ag Solutions- https://www.agconcepts.com/  320-219-3542Fast Lane Motorsports and powdercoating- http://www.fastlanemotorsports.orgEastCentral Sports- http://www.eastcentralsports.comFB- https://www.facebook.com/OnetoGoShowSpotify: https://open.spotify.com/episode/4fO19zPyhuwqb74Ut3jgho?si=clWSn-DVQkmp8W_f95p4IgTikTok- @theonetogoshowSnapchat-@theonetogoshowRumble:  https://rumble.com/v57phvx-71524-the-one-to-go-show-presented-by-impact-health-sharing.htmlYouTube: https://www.youtube.com/channel/UC_r_TSMx2XEfMfJ9Vc1ez0w?view_as=subscriberWe'd like to hear from you: theonetogoshow@gmail.comA productionof G.O.A.T. Sports Media LLC

The 2025 Bengals season is here — and we're breaking it all down on Episode 143 of the Cincy Sports Scene Podcast! From spicy quick hitters on FCC, UC, and the Reds, to our full game-by-game predictions for Joe Burrow and the Bengals, this episode is packed with debate, hot takes, and interactive challenges.

Chad Brendel of Bearcat Journal joined us to talk about the UC football team, on ESPN1530.Podcasts of The Mo Egger Radio Show are a service of Longnecks Sports Grill.Listen to the show live weekday afternoons 3:00 - 6:00 on ESPN1530. Listen Live: ESPN1530.com/listenGet more: https://linktr.ee/MoEggerFollow on X: @MoEggerInstagram too: @MoEgger

Chad Brendel of Bearcat Journal joined us to talk about the UC football team, on ESPN1530.Podcasts of The Mo Egger Radio Show are a service of Longnecks Sports Grill.Listen to the show live weekday afternoons 3:00 - 6:00 on ESPN1530. Listen Live: ESPN1530.com/listenGet more: https://linktr.ee/MoEggerFollow on X: @MoEggerInstagram too: @MoEgger

International Marriages, Ne Zha 2, Language Frameworks, + English & Japanese Subtitles for Learners 国際結婚、ナタ:魔導の大暴れ、言語枠組みなど！ Today we talk about what international marriages are most common between Japanese men and women and why that might be! International Marriage Article: https://news.yahoo.co.jp/expert/articles/7258a8b640d48dfddffeaedcf6f8720f1e4b1a15 Send us questions at:  lazyfluency@gmail.com Join the Community: Discord: https://discord.gg/VGSd94Tp4P Book Club! https://discord.com/channels/1204531163377442866/1402788543721508977 Support on ko-fi:  https://ko-fi.com/lazyfluency Follow us: Main channel:  https://www.youtube.com/channel/UC-8_djC5_aV4Mi3o3fuLPLA Instagram:https://www.instagram.com/lazyfluency/ Twitter: https://twitter.com/lazyfluency  

Rod and Karen banter about going back to a restaurant, heavy machinery, fried deviled eggs, brisket burgers and local business names Then they discuss CDC cuts, CHP to protect Kamala Harris, Cracker Barrel scrubs DEI pages, UC gets rid of African American student center, Black 2 Class Block Party canceled, Lil Yachty George Floyd bars, Spirit Airlines declares bankruptcy again, casino closing, Klarna sells debt to Nel-Net, King Harris, Wowdy HBTL, woman kills grandma by withholding insulin, man tries to kidnap barista, bowling alley kingpin and sword ratchetness. Patreon: https://www.patreon.com/theblackguywhotips Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@rodimusprime⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@SayDatAgain⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@TBGWT⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@TheBlackGuyWhoTips⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠theblackguywhotips@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Blog: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.theblackguywhotips.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Teepublic Store⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Amazon Wishlist⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Crowdcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Voicemail: ‪(980) 500-9034Go Premium: https://www.theblackguywhotips.com/premium/See omnystudio.com/listener for privacy information.

Good Morning and E News: Taylor and Travis went to the UC game!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On Friday's show: UC's 2025 season opener had a lot of 2024 in it, and yes, it's okay that the school accepted millions to move the game to KC.Sam LeCure talked about the fading Reds. Dax McCarty chatted about FC Cincinnati's showdown with Philly. Tony Pike talked about the Bengals. Mo talked about two legends.Podcasts of The Mo Egger Radio Show are a service of Longnecks Sports Grill.Listen to the show live weekday afternoons 3:00 - 6:00 on ESPN1530. Listen Live: ESPN1530.com/listenGet more: https://linktr.ee/MoEggerFollow on X: @MoEggerInstagram too: @MoEgger

On Friday's show: UC's 2025 season opener had a lot of 2024 in it, and yes, it's okay that the school accepted millions to move the game to KC.Sam LeCure talked about the fading Reds. Dax McCarty chatted about FC Cincinnati's showdown with Philly. Tony Pike talked about the Bengals. Mo talked about two legends.Podcasts of The Mo Egger Radio Show are a service of Longnecks Sports Grill.Listen to the show live weekday afternoons 3:00 - 6:00 on ESPN1530. Listen Live: ESPN1530.com/listenGet more: https://linktr.ee/MoEggerFollow on X: @MoEggerInstagram too: @MoEgger

The Megacanners are back, and they're not the only ones. After a busy summer of trying to sound important in America, Friedrich Merz is back in Berlin to ring in his so-called autumn of reforms, by which he means cutting the welfare state and making poor people join the army. Meanwhile, Robert Habeck, not wishing to rattle his chains as a ghost in parliament anymore, takes a swipe at nemesis Markus Söder and his affinity for sausages before disappearing to California. See ya mate! Megan's Megacan theme song by Eden Ottignon from ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Planet OTT⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Buy us a round, ask us a question! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/megansmegacan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Or follow us on whichever psychotic billionaire's data-fracking machine you prefer:https://www.instagram.com/megansmegacan/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/megansmegacan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/MegansMegacan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UC-o_U5nqe4_-yKfOm1CXOPA⁠⁠⁠⁠

SUBSCRIBE to The One to Go Show presented by ImpactHealth SharingSoil & Ag Solutions- https://www.agconcepts.com/  320-219-3542Fast Lane Motorsports and powdercoating- http://www.fastlanemotorsports.orgEastCentral Sports- http://www.eastcentralsports.comFB- https://www.facebook.com/OnetoGoShowSpotify: https://open.spotify.com/episode/4fO19zPyhuwqb74Ut3jgho?si=clWSn-DVQkmp8W_f95p4IgTikTok- @theonetogoshowSnapchat-@theonetogoshowRumble:  https://rumble.com/v57phvx-71524-the-one-to-go-show-presented-by-impact-health-sharing.htmlYouTube: https://www.youtube.com/channel/UC_r_TSMx2XEfMfJ9Vc1ez0w?view_as=subscriberWe'd like to hear from you: theonetogoshow@gmail.comA productionof G.O.A.T. Sports Media LLC

ESPN's Roddy Jones previews tonight's matchup between Nebraska and UC.

If you work in the almond industry, you likely know non-infectious bud failure (NBF) is bad news. However, do you understand why NBF happens, and that we're likely to see it on future almond varieties, not just on Carmel? Tom Gradziel discusses the science behind NBF and the work UC researchers together with nurseries have done to make massive gains in addressing the problem. You can lead more about managing NBF at: sacvalleyorchards.com/almonds/horticulture/non-infectious-bud-failure-management Come to an upcoming extension meeting!2025 International School on Microirrigation for Crop Production: Class Lectures at UC Davis October 13-15, and field trips October 16-17. The views, thoughts, and opinions expressed are the speaker's own and do not represent the views, thoughts, and opinions of the University of California. The material and information presented here is for general information purposes only. The "University of California" name and all forms and abbreviations are the property of its owner and its use does not imply endorsement of or opposition to any specific organization, product, or service.Follow us on Twitter! @SacOrchards and @SJVtandvThank you to the Almond, Pistachio, Prune, and Walnut Boards of California for their kind donations. Thank you to Muriel Gordon for the music.

Reminder to LIKE and SUBSCRIBE! Parks is back to preview week 1 of the Nebraska Football season. In the Battle Sports KC Classic, the Huskers meet up with the Cincinnati Bearcats for the first time since 1906!Parks takes a look at each position group for UC, and what Nebraska needs to do to win the game and start 1-0 again in 2025.Drop your score prediction in the YouTube video comments for a chance to win a free No Rivals cap!Shop FullRideVintageGear.com and use code PTFS at checkout for FREE shipping + 10% off your order. Shout out Full Ride Vintage Gear. GBR!

Send us a textFor two decades, Rachel Gebhardt has navigated the complex terrain of Crohn's disease with a refreshing perspective shaped by her father's experience with the same condition. Where her father let illness define him, Rachel chose a different path—one filled with humor, openness, and resilience—despite her case being more medically severe.Rachel's journey encompasses four bowel surgeries and fourteen hospital admissions since 2020 alone, including a colostomy she affectionately named "Whoopie." With disarming candor, she shares the moment her surgeon showed her a photo of a woman in an American flag bikini with a matching ostomy bag cover as encouragement—a moment that eventually inspired her own celebratory beachside photo years later. Through skin infections, bowel obstructions, and dietary restrictions, Rachel maintains her commitment to living fully and modeling positive coping for her children.The military healthcare system presented unique challenges, but also connected Rachel with Dr. Anish Patel at Brook Army Medical Center, who became not just her gastroenterologist but her advocate and ally. Their relationship exemplifies the profound difference compassionate, specialized care makes for patients with complex conditions. Rachel details her experience with hyperbaric treatments, medication complications, and the surprising remission she experienced only during pregnancy and breastfeeding—highlighting the understudied connection between hormones and IBD.What resonates most deeply is Rachel's transformation from initially viewing her ostomy as "the end of the world" to embracing it as a source of freedom. Now training for a half marathon and hiking mountains previously inaccessible when bathroom urgency controlled her life, she's become an outspoken advocate for ostomy awareness. Her message is clear and powerful: life with an ostomy can be not just manageable, but genuinely good—a perspective desperately needed by those facing similar paths. For anyone navigating IBD or supporting someone who is, Rachel's story offers both practical wisdom and heartening hope.Links: United Ostomy AssociationOur episode with Dr. Anish PatelPregnancy and Crohn's - video from Brigham & Women's IBD CenterPregnancy & Breastfeeding info- Crohn's Colitis UKLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Comprehensive coverage of the day's news with a focus on war and peace; social, environmental and economic justice. Trump issues Executive Order to create National Guard units to quell unrest, end cash bail, and send flag burners to jail; UC law school dean Chemerinsky discusses Trump executive orders with KPFA; Democratic leaders blast Trump sending troops to democrat-run cities; California celebrates Transgender History Month as trans people face attacks from Trump administration; Illinois becomes first state to create legal advice line “Illinois Pride Connect” for LGBTQ residents; Israel hits Gaza hospital with missile, then second strike as medics, journalists rush to help, killing 20 The post Trump Executive Order creates National Guard units to quell unrest; Democratic leaders blast Trump sending troops to democrat-run cities – August 25, 2025 appeared first on KPFA.

Useless Jobs, Okinawa's Koshien Victory, Improvement & Language Learning, + English & Japanese Subtitles for Learners 無駄な仕事、沖縄の甲子園での勝利、言語学習の上達など！ Japan has a lot of busy work? Today we talk about if there is a point to any it! Send us questions at:  lazyfluency@gmail.com Join the Community: Discord: https://discord.gg/VGSd94Tp4P Book Club! https://discord.com/channels/1204531163377442866/1402788543721508977 Support on ko-fi:  https://ko-fi.com/lazyfluency Follow us: Main channel:  https://www.youtube.com/channel/UC-8_djC5_aV4Mi3o3fuLPLA Instagram:https://www.instagram.com/lazyfluency/ Twitter: https://twitter.com/lazyfluency  

On Thursday's show...Can we trust the Reds' bullpen? Should the Reds have sent down Matt McLain months ago? Can we stop talking about a "league-average defense"?  Plus...Tony Pike with hourly Bengals training camp updaes, Lee Sterling on Week 0 college football betting, Dan Clasgens with fantasy football draft advice, and Chad Brendel on UC football and basketball.Podcasts of The Mo Egger Radio Show are a service of Longnecks Sports Grill.Listen to the show live weekday afternoons 3:00 - 6:00 on ESPN1530. Listen Live: ESPN1530.com/listenGet more: https://linktr.ee/MoEggerFollow on X: @MoEggerInstagram too: @MoEgger

On Thursday's show...Can we trust the Reds' bullpen? Should the Reds have sent down Matt McLain months ago? Can we stop talking about a "league-average defense"?  Plus...Tony Pike with hourly Bengals training camp updaes, Lee Sterling on Week 0 college football betting, Dan Clasgens with fantasy football draft advice, and Chad Brendel on UC football and basketball.Podcasts of The Mo Egger Radio Show are a service of Longnecks Sports Grill.Listen to the show live weekday afternoons 3:00 - 6:00 on ESPN1530. Listen Live: ESPN1530.com/listenGet more: https://linktr.ee/MoEggerFollow on X: @MoEggerInstagram too: @MoEgger

  Lawmakers call on UC to return all Native remains and items   Trump reacts to 9th Circuit's last-minute block on Oak Flat land swap   Sault Ste. Marie Tribe of Chippewa Indians donates $200k to Rx Kids  

SUBSCRIBE to The One to Go Show presented by ImpactHealth SharingSoil & Ag Solutions- https://www.agconcepts.com/  320-219-3542Fast Lane Motorsports and powdercoating- http://www.fastlanemotorsports.orgEastCentral Sports- http://www.eastcentralsports.comFB- https://www.facebook.com/OnetoGoShowSpotify: https://open.spotify.com/episode/4fO19zPyhuwqb74Ut3jgho?si=clWSn-DVQkmp8W_f95p4IgTikTok- @theonetogoshowSnapchat-@theonetogoshowRumble:  https://rumble.com/v57phvx-71524-the-one-to-go-show-presented-by-impact-health-sharing.htmlYouTube: https://www.youtube.com/channel/UC_r_TSMx2XEfMfJ9Vc1ez0w?view_as=subscriberWe'd like to hear from you: theonetogoshow@gmail.comA productionof G.O.A.T. Sports Media LLC

Lance and Bengals/UC play-by-play voice Dan Hoard discuss the Bengals' roster and preview UC football's Week 1 matchup against Nebraska.

Chad Brendel joins us to look ahead to the UC football season and the impact of Jizzle James' departure on the Bearcats basketball program.Podcasts of The Mo Egger Radio Show are a service of Longnecks Sports Grill.Listen to the show live weekday afternoons 3:00 - 6:00 on ESPN1530. Listen Live: ESPN1530.com/listenGet more: https://linktr.ee/MoEggerFollow on X: @MoEggerInstagram too: @MoEgger

Chad Brendel joins us to look ahead to the UC football season and the impact of Jizzle James' departure on the Bearcats basketball program.Podcasts of The Mo Egger Radio Show are a service of Longnecks Sports Grill.Listen to the show live weekday afternoons 3:00 - 6:00 on ESPN1530. Listen Live: ESPN1530.com/listenGet more: https://linktr.ee/MoEggerFollow on X: @MoEggerInstagram too: @MoEgger

The Nebraska Cornhuskers are coming off a 7-win season, but there's a belief in Lincoln that this is the year Matt Rhule and company will take the next step. How do the Cornhuskers match up with the Bearcats? Connor Happer of the Nebraska media scene joins the program to break it down. Find our show on YouTube! Interested in sponsoring the fastest growing UC channel in the world? Contact: CWalterbroadcast@gmail.com to discuss potential partnerships.

Clare joins Dr. Lowrie for a good conversation on what to expect in Cardio-Pulm. Sarah then talks to David Neiling, UC's Learning Specialist, to record some tips and tricks for studying for the block and starting to plan for Step 1. Good luck! You can do it!Send us a text

Clare joins Dr. Christensen for a good conversation on what to expect in SFOM and how the curriculum has changed in recent years. Sarah then talks to David Neiling, UC's Learning Specialist, to record some tips and tricks for studying for the block and starting M1. Good luck! You can do it!Send us a text

  Oak Flat protectors get 'last-minute' win in appeals court ruling   Lawmakers highlight UC repatriation of Native remains and items   Camas bulb bake-off in Oregon features traditional recipes  

It's the “Second Chance” edition of the Bengals Booth Podcast as Cincinnati gets ready for its second preseason game at Washington. Dan Hoard's guests include rookie center Seth McLaughlin, former UC and NFL quarterback Tony Pike, and a Cincinnati Reds pitcher who loves the Orange and Black.See omnystudio.com/listener for privacy information.

A federal judge in San Francisco on Tuesday ordered the Trump administration to restore more than $80 million in grants it withheld from UCLA. The ruling comes as the government accuses the university of antisemitism on campus and discrimination in admissions. To resolve the funding freeze, Trump is demanding a $1 billion settlement, which Governor Gavin Newsom characterizes as extortion and UC officials say would “completely devastate” the public university system. We look at how UCLA and other universities are responding to Trump's pressure campaign. Guests: Jaweed Kaleem, education reporter, The Los Angeles Times Eric Kelderman, senior writer, The Chronicle of Higher Education Siobhan Braybrook, associate professor, UCLA Learn more about your ad choices. Visit megaphone.fm/adchoices